Work

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Year: 2018

Type: article

Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children 1 . Pediatric patients with disease refractory to last chemotherapy, relapse after allogeneic hematopoietic stem-cell transplantation (alloHSCT), or second or further relapse have a particularly poor prognosis 2 . Intensive chemotherapy followed by alloHSCT after achieving remission can result in cure for some patients. However, survival is still low with this approach 3 . Thus, additional treatment modalities with acceptable toxicity are needed to improve long-term survival.

Source: Blood Cancer Journal

DOI: 10.1038/s41408-018-0117-0

Authors: Lia Gore, Franco Locatelli, Gerhard Zugmaier, Rupert Handgretinger, Maureen M. O’Brien, Peter Bader, Deepa Bhojwani, Paul-Gerhardt Schlegel, Catherine A. Tuglus, Arend von Stackelberg

Institutions: Children's Hospital Colorado, University of Colorado Anschutz, University of Pavia, Bambino Gesù Children's Hospital, Amgen (Germany), University of Tübingen, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Goethe University Frankfurt, University Hospital Frankfurt, Children's Hospital Los Angeles, University of Würzburg, Universitätsklinikum Würzburg, Amgen (United States), Stiftung Charité, Charité – Universitätsmedizin Berlin

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,290

Funders: Amgen, European Commission

Award: International study for treatment of childhood relapsed ALL 2010 with standard therapy, systematic integration of new agents, and establishment of standardized diagnostic and research

OpenAlex ID: W2888107969

FWCI: 10.47

Cites: 8

Cited by: 90

Related to: 10